Credit Suisse rated Outperform AbbVie (NYSE: ABBV) on 10/09/2013, when the stock price was $44.69. Since then, AbbVie has gained 44.35% as of 12/01/2015's recent price of $64.51.
If you would have followed this Credit Suisse's recommendation on ABBV, you would have gained 44.34% of your investment in 783 days.



Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.

Marked as spam